



Corrigendum

Corrigendum to “An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature” [Vaccine 36(21) 3054–3060]



Elisabeth J.M. Huijbers^a, Judy R. van Beijnum^a, Chung T. Lê^a, Sophia Langman^a, Patrycja Nowak-Sliwinska^b, Kevin H. Mayo^c, Arjan W. Griffioen^{a,*}

^a Angiogenesis Laboratory, Cancer Center Amsterdam, Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands

^b School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland

^c Department of Biochemistry, Molecular Biology & Biophysics, University of Minnesota, Minneapolis, MN, USA

The authors of Huijbers et al. [1] apologize for not giving sufficient credit to the work presented by Saupe et al. [2], Huijbers et al. [3] and Femel et al. [4]. Below are corrections to the relevant parts of the article. The authors would like to apologize for any inconvenience caused.

Page 3054 (Introduction)

The sentence: ‘In previous work we have shown that it is possible to break self-tolerance in mice, and to induce antibody responses against the tumor vascular markers extra domain A (EDA) and B (EDB) of the extracellular matrix molecule fibronectin.’

should be replaced by:

‘Previous work of Huijbers et al. [3] and Femel et al. [4] has shown that it is possible to break self-tolerance in mice, and to induce antibody responses against the tumor vascular markers extra domain A (EDA) and B (EDB) of the extracellular matrix molecule fibronectin.’

Page 3056 (Discussion)

The sentence: ‘We have previously shown that the anti-self antibody response against EDB is decreased as the amount of TRX is increased.’

should be replaced by:

‘Saupe et al. [2] have previously shown that the anti-self antibody response against EDB is decreased as the amount of TRX is increased.’

Page 3057 (Discussion)

The sentence: ‘In this paper we show that the TRX-part is absolutely required to induce an immune response against EDB and that vaccination with EDB alone does not induce an antibody response against EDB.’

should be replaced by:

‘In this paper Saupe et al. [2] show that the TRX-part is absolutely required to induce an immune response against EDB and

that vaccination with EDB alone does not induce an antibody response against EDB.’

Page 3058 (Discussion)

The sentence: ‘To address this issue, we have previously used the MMTV-PyMT transgenic model of breast cancer. Since EDB is not expressed in this model we approached the question with a vaccine against the extra domain A of fibronectin (EDA).’

should be replaced by:

‘This issue was previously addressed by Femel et al. [4] using the MMTV-PyMT transgenic model of breast cancer. Since EDB is not expressed in this model the question was approached with a vaccine against the extra domain A of fibronectin (EDA).’

The sentence: ‘We have looked into more detail at the immune response induced with the TRX-EDB vaccine [12] and found that the major subclass induced by the vaccine was IgG1, which is characteristic of a Th2-response, thus an antibody mediated immune response in mice. Furthermore, we found macrophages trying to engulf the tumor vessels in the tumors of mice vaccinated with TRX-EDB, increased fibrinogen leakage and increased neutrophil infiltration in these tumors.’

should be replaced by:

‘Huijbers et al. [3] have looked into more detail at the immune response induced with the TRX-EDB vaccine and found that the major subclass induced by the vaccine was IgG1, which is characteristic of a Th2-response, thus an antibody mediated immune response in mice. Furthermore, they found macrophages trying to engulf the tumor vessels in the tumors of mice vaccinated with TRX-EDB, increased fibrinogen leakage and increased neutrophil infiltration in these tumors.’

After the sentence: ‘The current study demonstrates that several alternative non-self fusion partners in conjugate vaccines can elicit strong and specific antibody responses against self-antigens.’

this sentence should be added:

‘This was also observed in a study by Saupe et al. in which VLRB (variable lymphocyte receptor B) conjugate vaccines were used [2]. This study concluded that the foreign antigen should be short

DOI of original article: <https://doi.org/10.1016/j.vaccine.2018.03.064>

* Corresponding author.

E-mail address: aw.griffioen@vumc.nl (A.W. Griffioen).

(around 41 aa in size), have multimerizing capacity to provide a strong B cell activation signal and be hidden inside the vaccine protein to avoid epitope masking or clearance of the fusion protein.'

Page 3058 (Experimental procedures)

The sentence: 'The pET21-TRX vector was a kind gift of Dr. Anna-Karin Olsson (Uppsala University, Uppsala, Sweden).', should be replaced by:

'Both the pET21-TRX vector and the pET21a-TRX-EDB vector were a kind gift of Dr. Anna-Karin Olsson (Uppsala University, Uppsala, Sweden).'

References

- [1] Huijbers EJM, Van Beijnum JR, Le CT, Langman S, Patrycja Nowak-Sliwinska P, Mayo KH, et al. An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature. *Vaccine* 2018;36:3054–60.
- [2] Saupé F, Reichel M, Huijbers EJ, Femel J, Markgren PO, Andersson CE, et al. Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously. *FASEB J* 2017;31:1204–14.
- [3] Huijbers EJ, Ringvall M, Femel J, Kalamajski S, Lukinius A, Abrink M, et al. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. *Faseb J* 2010;24:4535–44.
- [4] Femel J, Huijbers EJ, Saupé F, Cedervall J, Zhang L, Roswall P, et al. Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer. *Oncotarget* 2014;5:12418–27.